These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12478006)

  • 21. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
    Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
    Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy.
    Gutman H; Schachter J; Stopel E; Gutman R; Lahav J
    Cancer; 2002 Feb; 94(3):780-5. PubMed ID: 11857313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of allogenic and autologous transfusion on immune function in patients with tumors.
    Guo JR; Xu F; Jin XJ; Shen HC; Liu Y; Zhang YW; Shao Y
    Asian Pac J Cancer Prev; 2014; 15(1):467-74. PubMed ID: 24528076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma.
    Cartei G; Sala PG; Sanzari M; Ceschia V; Clocchiatti L; Sibau A; Donà S; Giovannoni M; Vigevani E
    J Am Acad Dermatol; 1993 May; 28(5 Pt 1):738-44. PubMed ID: 8496418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
    Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
    Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
    Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
    Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome.
    Koçar IH; Yesilova Z; Ozata M; Turan M; Sengül A; Ozdemir I
    Clin Exp Immunol; 2000 Sep; 121(3):448-52. PubMed ID: 10973715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.
    Hernberg M; Mattila PS; Rissanen M; Hansson J; Aamdal S; Bastholt L; von der Maase H; Schmidt H; Stierner U; Tarkkanen J
    J Immunother; 2007 Oct; 30(7):773-9. PubMed ID: 17893569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the subgroups of T, B, natural killer lymphocyte and serum levels of interleukin-15, interleukin-21 and immunoglobulin E in the pathogenesis of urticaria.
    Huilan Z; Runxiang L; Bihua L; Qing G
    J Dermatol; 2010 May; 37(5):441-7. PubMed ID: 20536649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
    Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
    Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
    Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
    Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lymphocyte subpopulations, levels of interferon, and expression of their receptors in patients with chronic hepatitis B and C: Correlation with the species of viruses and the degree of liver fibrosis].
    Kalyuzhin OV; Ponezheva ZB; Semenova IV; Khokhlova ON; Serebrovskaya LV; Guseva TS; Parshina OV; Maleev VV
    Ter Arkh; 2017; 89(11):14-20. PubMed ID: 29260741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevation of interleukin-10 levels in malignant pleural effusion.
    Chen YM; Yang WK; Whang-Peng J; Kuo BI; Perng RP
    Chest; 1996 Aug; 110(2):433-6. PubMed ID: 8697847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.